scholarly journals High risk of recurrent venous thrombosis in patients with lower-leg cast immobilization

2018 ◽  
Vol 16 (11) ◽  
pp. 2218-2222 ◽  
Author(s):  
B. Nemeth ◽  
J. F. Timp ◽  
A. van Hylckama Vlieg ◽  
F. R. Rosendaal ◽  
S. C. Cannegieter
Keyword(s):  
High Risk ◽  
Venous Thrombosis ◽  
Lower Leg ◽  
Cast Immobilization ◽  
Recurrent Venous Thrombosis

Individualized Thromboprophylaxis in Patients with Lower-Leg Cast Immobilization—A Validation and Subgroup Analysis in the POT-CAST Trial

2019 ◽  
Vol 119 (09) ◽  
pp. 1508-1516 ◽  
Author(s):  
Banne Nemeth ◽  
Raymond van Adrichem ◽  
Rob Nelissen ◽  
Saskia le Cessie ◽  
Suzanne C. Cannegieter
Keyword(s):  
Risk Factors ◽  
High Risk ◽  
Achilles Tendon Rupture ◽  
Area Under The Curve ◽  
Risk Groups ◽  
Lower Leg ◽  
Risk Category ◽  
Cast Immobilization ◽  
Relative Risks ◽  
Small Subgroup

Background A small subgroup of patients treated with lower-leg cast immobilization develops venous thromboembolism (VTE). Objectives (1) Identify risk factors for VTE in patients with cast immobilization, (2) assess the effectiveness of thromboprophylaxis in low- and high-risk groups, and (3) validate the performance of the L-TRiP(cast) score. Methods Data from the POT-CAST trial were used. A total of 1,519 patients with lower-leg cast immobilization were randomized to a prophylactic dose of low-molecular-weight heparin or no treatment. Primary outcome: symptomatic VTE within 3 months. Absolute risks (ARs) were determined for low- and high-risk subgroups. For several risk factors, relative risks (RRs) for VTE were estimated with corresponding 95% confidence intervals (CIs). For validating the L-TRiP(cast) score, a discrimination and calibration analysis were performed. Results Patients with a body mass index of > 30 kg/m2 and those with a VTE in their family history had an increased VTE risk, RR 3.8 (95% CI, 1.5–9.4) and RR 2.4 (95% CI, 1.0–5.6), respectively. Concerning injury-specific risk factors, patients with an Achilles tendon rupture or those who were surgically treated had the highest risk of VTE, AR at 8.5% (95% CI, 3.7–16.1) and AR 3.5% (95% CI, 1.3–7.5), respectively. There were no subgroups in which thromboprophylaxis was effective for prevention of symptomatic VTE. The area under the curve for the L-TRiP(cast) score was 0.69 (95% CI, 0.58–0.80). Conclusion Thromboprophylaxis was not effective for VTE prevention following lower-leg cast immobilization in any risk category. Low- and high-risk individuals could be identified using the L-TRiP(cast) score. The best treatment strategy for these patients is yet to be determined.

Possible contribution of cytomegalovirus infection to the high risk of (recurrent) venous thrombosis after renal transplantation

2008 ◽  
Vol 99 (01) ◽  
pp. 127-130 ◽  
Author(s):  
Aiko P. J. de Vries ◽  
Nic J. G. M Veeger ◽  
Willem J. van Son ◽  
Stephan J. L Bakker ◽  
Jan van der Meer ◽  
...  
Keyword(s):  
High Risk ◽  
Renal Transplant ◽  
Venous Thrombosis ◽  
Case Reports ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Cmv Infection ◽  
Increased Risk ◽  
Recurrent Venous Thrombosis ◽  
Cmv Status

SummaryRenal transplant recipients are at an increased risk of venous thrombosis, which has been regarded as a postoperative complication, although it may persist afterwards. As numerous case reports have shown that active cytomegalovirus (CMV) infection can be found at time of onset of venous thrombosis, and is frequently found in renal transplant recipients, we hypothesized that one might be the result of the other. To calculate the risk of (recurrent) venous thrombosis in renal transplant recipients, and to see whether CMV infection influenced this risk, we retrospectively analysed 606 living consecutive renal transplant recipients. CMV status at time of transplantation and at time of enrolment was determined. Absolute risks of first venous thrombosis and recurrence were compared with CMV status, and were corrected for surgery related venous thrombosis, age, and anticoagulant treatment. Annual incidence of venous thrombosis was 0.88% (95% CI, 0.65–1.15) in all recipients and 0.59% (95% CI,0.41–0.83) corrected for surgery related venous thrombosis. CMV positive and seroconverted recipients tended to have an increased risk of venous thrombosis compared to CMV negative recipients; corrected relative risks were 2.0 (95% CI, 0.9–5.2) and 1.7 (95% CI, 0.6–4.7), respectively. The cumulative 10-year recurrence rate of venous thrombosis in CMV seronegative, seroconverted, and seropositive recipients was 10%,51% and 59%, respectively. We conclude that CMV infection tended to be associated with an increased risk of (recurrent) venous thrombosis. Prospective studies are warranted to establish this observation, which suggests that CMV infection influences the high risk of (recurrent) venous thrombosis in renal transplant recipients.

Predisposing factors for first and recurrent venous thrombosis

ESC CardioMed ◽  
2018 ◽  
pp. 2751-2755
Author(s):  
Willem M. Lijfering ◽  
Suzanne C. Cannegieter
Keyword(s):  
Risk Factors ◽  
Risk Factor ◽  
High Risk ◽  
Venous Thrombosis ◽  
Case Fatality ◽  
Predisposing Factors ◽  
Medical Illness ◽  
Vein Thrombosis ◽  
Patient Will ◽  
Recurrent Venous Thrombosis

Venous thrombosis, which mainly manifests as deep vein thrombosis of the leg or pulmonary embolism, is a major contributor to global disease burden. With a recurrence rate of approximately 25% in 5 years, and a 30-day case fatality rate of 5–10%, identification of predisposing factors for venous thrombosis is imperative. Dozens of risk factors for first venous thrombosis are known today, which can be grouped into three categories: first venous thrombosis ‘provoked by a transient risk factor’, ‘provoked by a persistent risk factor’, or ‘unprovoked’. This chapter comments on how risk factors known today can be classified into these categories, how this classification determines recurrence risk, and how knowledge on predisposing risk factors should be interpreted and integrated for optimal clinical use. The chapter proposes that predisposing factors for venous thrombosis are not the same for each high-risk situation. This is important to consider when one wants to identify high-risk groups in, for example, cancer patients, surgical patients, in patients with a medical illness, or in patients at risk for recurrent venous thrombosis. This way it will be possible to expose only those patients at unacceptably high risk of thrombosis to the risks and burden of anticoagulant treatment. In conclusion, the knowledge on predisposing factors for venous thrombosis is extensive, but the patient will benefit most when this knowledge is properly integrated, depending on the clinical situation.

The Prevalence of Hereditary Antithrombin-III Deficiency in Patients with a History of Venous Thromboembolism

1985 ◽  
Vol 54 (04) ◽  
pp. 744-745 ◽  
Author(s):  
R Vikydal ◽  
C Korninger ◽  
P A Kyrle ◽  
H Niessner ◽  
I Pabinger ◽  
...  
Keyword(s):  
Venous Thrombosis ◽  
Antithrombin Iii ◽  
Positive Family History ◽  
Normal Range ◽  
The Family ◽  
History Of ◽  
Antithrombin Iii Deficiency ◽  
Recurrent Venous Thrombosis ◽  
Antithrombin Iii Activity ◽  
Slight Deficiency

SummaryAntithrombin-III activity was determined in 752 patients with a history of venous thrombosis and/or pulmonary embolism. 54 patients (7.18%) had an antithrombin-III activity below the normal range. Among these were 13 patients (1.73%) with proven hereditary deficiency. 14 patients were judged to have probable hereditary antithrombin-III deficiency, because they had a positive family history, but antithrombin-III deficiency could not be verified in other members of the family. In the 27 remaining patients (most of them with only slight deficiency) hereditary antithrombin-III deficiency was unlikely. The prevalence of hereditary antithrombin-III deficiency was higher in patients with recurrent venous thrombosis.

Clinical Utility of Real-Time Compression Ultrasonography for Diagnostic Management of Patients with Recurrent Venous Thrombosis

1992 ◽  
Vol 33 (4) ◽  
pp. 297-300 ◽  
Author(s):  
H. Heijboer ◽  
L. M. M. Jongbloets ◽  
H. R. Buller ◽  
A. W. A. Lensing ◽  
J. W. Ten Cate
Keyword(s):  
Venous Thrombosis ◽  
Real Time ◽  
Clinical Utility ◽  
Time Compression ◽  
Diagnostic Management ◽  
Recurrent Venous Thrombosis ◽  
Compression Ultrasonography

scholarly journals Forty-One-Year-Old Man with Pulmonary Embolism 5 Months After COVID-19

2021 ◽  
Vol 15 ◽  
pp. 117954842098665
Author(s):  
Muhanad Taha ◽  
Paul Nguyen ◽  
Aditi Sharma ◽  
Mazen Taha ◽  
Lobelia Samavati
Keyword(s):  
Risk Factors ◽  
Pulmonary Embolism ◽  
Venous Thromboembolism ◽  
High Risk ◽  
Venous Thrombosis ◽  
Case Summary ◽  
One Year

Background: Hypercoagulation is one of the striking features of COVID-19. Patients hospitalized with COVID-19 are at high risk for venous thromboembolism. However, it is unknown if the risk for venous thromboembolism persists after discharge. Case Summary: We report a case with pulmonary embolism 5 months after COVID-19. No risk factors for venous thrombosis have been identified. Conclusion: In COVID-19 related hospitalization, large studies are needed to identify the risk of venous thromboembolism after discharge.

The Use of Indium-111 Labeled Platelet Scanning for the Detection of Asymptomatic Deep Venous Thrombosis in a High Risk Population

Orthopedics ◽  
1989 ◽  
Vol 12 (11) ◽  
pp. 1439-1443
Author(s):  
Robert S Siegel ◽  
Janice L Rae ◽  
Nancy L Ryan ◽  
Cherie Edwards ◽  
William P Fortune ◽  
...  
Keyword(s):  
High Risk ◽  
Venous Thrombosis ◽  
Deep Venous Thrombosis ◽  
High Risk Population ◽  
Risk Population ◽  
Indium 111

scholarly journals Statin use and risk of recurrent venous thrombosis: results from the MEGA follow-up study

2017 ◽  
Vol 1 (1) ◽  
pp. 112-119 ◽  
Author(s):  
Sigrid K. Braekkan ◽  
Camila Caram-Deelder ◽  
Bob Siegerink ◽  
Astrid van Hylckama Vlieg ◽  
Saskia le Cessie ◽  
...  
Keyword(s):  
Venous Thrombosis ◽  
Follow Up Study ◽  
Recurrent Venous Thrombosis ◽  
Statin Use
Sign in / Sign up

Export Citation Format

Share Document